Login
Companies $CRMD
$4.82 +$0.00 (0.0%) After hours
CorMedix Inc. logo

CorMedix Inc.

cormedix.com

What Do They Do?

Sells DefenCath, an antimicrobial catheter-lock solution, and medicines for serious infections and cardiovascular conditions to dialysis providers, hospitals and clinics.

How Do They Make Money?

Product sales account for 98% of revenue; customers pay for products when they receive them.

revenue
SegmentShareRevenue
Product Sales, Net
Sold outright

98%
Contract revenue
2.4%

Who Are Their Customers?

Sells DefenCath directly to hospitals and outpatient dialysis center operators; its product customers also include outpatient service providers and wholesale distributors.

Do Revenues Turn Into Profits?

Yes. It kept 52 cents of every revenue dollar as net income in FY2025 and turned 55 cents into free cash flow.

Operating income, FY2025
48% of revenue
▲ Turned profitable vs FY2024 (−$22.4M, −51%)
Net income, FY2025
52% of revenue
▲ Turned profitable vs FY2024 (−$17.9M, −41%)
Free cash flow, FY2025
55% of revenue
▲ Turned profitable vs FY2024 (−$50.7M, −117%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −48%
vs $104.3M in Q3 FY2025
Net income
▼ Turned to a loss
vs $108.6M in Q3 FY2025
Product sales, net share of revenue vs 97.4% in Q3 FY2025
  • Nov 12, 2026 Agrees to acquire Heron assets and suspends 2027 DefenCath revenue guidance It maintained full-year 2026 revenue guidance and narrowed adjusted EBITDA guidance.
  • Jun 25, 2026 Replaces CBIZ CPAs with Ernst & Young as auditor

Growing. Revenue grew 1632.5x in 4 years, from $190.9K in FY2021 to $311.7M in FY2025, about 536% a year.

Broader commercial portfolio The older report centered on developing DefenCath and Neutrolin, including international commercialization; the latest describes U.S. DefenCath sales alongside marketed hospital- and clinic-focused infectious-disease and cardiovascular products.

Expanded indication development The older report described use of DefenCath for TPN patients as a possible future indication; the latest says a clinical study is underway for adults receiving TPN via central venous catheters.

Revenue over time
Product Sales, Net Contract revenue DefenCath
$500M$250M$0

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support